Tag Archives: Risk

Bristol Myers Squibb’s Opdivo cuts relapse risk in muscle-invasive bladder cancer

Bristol Myers Squibb’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease. The company revealed Thursday that its PD-1 fighter, against placebo, had lengthened the time muscle-invasive urothelial carcinoma patients could remain disease-free after surgery. All patients saw benefit,… Read More »